This topic addresses the implementation of next-generation sequencing (NGS) in cystic fibrosis newborn screening programs. It seeks to discuss how this technology affects referral rates, the classification of cases such as CRMS/CFSPID, and the specific challenges that arise during diagnostic follow-up.